ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL225071
CHEMBL225071
Compound Name RALTITREXED
ChEMBL Synonyms ZD-16 | RALTITREXED | TOMUDEX | ZD1694
Max Phase 4 (Approved)
Trade Names TOMUDEX
Molecular Formula C21H22N4O6S

Additional synonyms for CHEMBL225071 found using NCI Chemical Identifier Resolver

Compound Representations

Molfile Download MolFile
Canonical SMILES CN(Cc1ccc2NC(=NC(=O)c2c1)C)c3ccc(s3)C(=O)N[C@@H](CCC(=O)O)C( ...
Download SMILES
Standard InChI InChI=1S/C21H22N4O6S/c1-11-22-14-4-3-12(9-13(14)19(28)23-11) ...
Download InChI
Standard InChI Key IVTVGDXNLFLDRM-HNNXBMFYSA-N

Sources

  • BindingDB Database
  • British National Formulary
  • PubChem BioAssays
  • Scientific Literature
  • USP Dictionary of USAN and International Drug Names
  • WHO Anatomical Therapeutic Chemical Classification

Alternate Forms of Compound in ChEMBL


CHEMBL225071

Molecule Features

CHEMBL225071 compound icon
Drug Type:Synthetic Small Molecule Rule of Five:Y First In Class:N Chirality:Single Stereoisomer Prodrug:N Oral:N Parenteral:N Topical:N Black Box:N Availability Type:Unknown

Mechanism of Action

Mechanism of Action ChEMBL Target References
Thymidylate synthase inhibitor Thymidylate synthase PubMed PubMed

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
Nasopharyngeal NeoplasmsD009303EFO:0004252nasopharyngeal neoplasm2ClinicalTrials
Colorectal NeoplasmsD015179EFO:1001951colorectal carcinoma3ClinicalTrials
Rectal NeoplasmsD012004EFO:1000657rectum cancer2ClinicalTrials
Precursor Cell Lymphoblastic Leukemia-LymphomaD054198EFO:0000220acute lymphoblastic leukemia1ClinicalTrials
Esophageal NeoplasmsD004938EFO:0002916esophageal carcinoma2ClinicalTrials
Stomach NeoplasmsD013274EFO:0000178gastric carcinoma2ClinicalTrials
Carcinoma, Squamous CellD002294EFO:0000707squamous cell carcinoma3ClinicalTrials
Colorectal NeoplasmsD015179EFO:0005842colorectal cancer3ClinicalTrials
MesotheliomaD008654EFO:0000588mesothelioma3ClinicalTrials
NeoplasmsD009369EFO:0000616neoplasm4ATC
ClinicalTrials

Clinical Data

ClinicalTrials.gov RALTITREXED
The Cochrane Collaboration RALTITREXED

Compound Bioactivity Summary

Compound Assay Summary

Compound Target Summary

Target Predictions

The two tables below display ChEMBL single-protein targets which are predicted to interact with CHEMBL225071. A 1uM and 10 uM cut-off have been applied to ChEMBL bioactivity data used to generate the respective models and the yellow coloured rows correspond to genuine predictions, i.e. targets not included in the original training set for this compound.


1uM


ChEMBL_ID Target Name Organism Score
CHEMBL1952 Thymidylate synthase Homo sapiens 1.000
CHEMBL3160 Thymidylate synthase Mus musculus 1.000
CHEMBL3972 GAR transformylase Homo sapiens 1.000
CHEMBL2902 Dihydrofolate reductase Lactobacillus casei 1.000
CHEMBL4564 Dihydrofolate reductase Mus musculus 1.000
CHEMBL6137 Thymidylate synthase Escherichia coli 1.000
CHEMBL5328 Thymidylate synthase Lactobacillus casei 1.000
CHEMBL202 Dihydrofolate reductase Homo sapiens 0.999
CHEMBL2288 Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 Homo sapiens 0.783
CHEMBL325 Histone deacetylase 1 Homo sapiens 0.375



10uM


ChEMBL_ID Target Name Organism Score
CHEMBL1952 Thymidylate synthase Homo sapiens 1.000
CHEMBL3160 Thymidylate synthase Mus musculus 1.000
CHEMBL3972 GAR transformylase Homo sapiens 1.000
CHEMBL6137 Thymidylate synthase Escherichia coli 1.000
CHEMBL5328 Thymidylate synthase Lactobacillus casei 1.000
CHEMBL2902 Dihydrofolate reductase Lactobacillus casei 1.000
CHEMBL4564 Dihydrofolate reductase Mus musculus 1.000
CHEMBL2288 Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 Homo sapiens 1.000
CHEMBL202 Dihydrofolate reductase Homo sapiens 0.999

Calculated Compound Parent Properties

Mol. Weight Mol. Weight Monoisotopic ALogP #Rotatable Bonds Polar Surface Area Molecular Species
458.5 458.126 1.98 9 152.69 ACID


HBA HBD #Ro5 Violations HBA (Lipinski) HBD (Lipinski) #Ro5 Violations (Lipinski)
7 4 0 10 4 0


ACD Acidic pKa ACD Basic pKa ACD LogP ACD LogD pH7.4 Aromatic Rings Heavy Atoms QED Weighted
3.5 2.55 .85 -3.88 3 32 0.38

Structural Alerts

There are 2 structural alerts for CHEMBL225071. To view alerts please click here.

Compound Cross References

ATC L - ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 - ANTINEOPLASTIC AGENTS
L01B - ANTIMETABOLITES
L01BA - Folic acid analogues
L01BA03 - raltitrexed

ChemSpider ChemSpider:IVTVGDXNLFLDRM-HNNXBMFYSA-N
PubChem SID: 144205790 SID: 144207198 SID: 49681782 SID: 499545
Wikipedia Raltitrexed

UniChem Cross References

View the UniChem Connectivity matches for CHEMBL225071



ACToR 112887-68-0
BindingDB 18795 50027655
Brenda 209748 13332 143744 3165 32433
ChEBI 5847
ChemicalBook CB1222070
DrugBank DB00293
DrugCentral 2353
eMolecules 2729965
EPA CompTox Dashboard DTXSID0046482
FDA SRS FCB9EGG971
Guide to Pharmacology 7403
Human Metabolome Database HMDB0014438
IBM Patent System F0B20A7C299634CDF3DD465BDF1BFF00 A41E4F603A2A40C059E60DE85A51D952
KEGG Ligand C11372
LINCS LSM-5952
MolPort MolPort-006-167-509 MolPort-003-850-114
NIH Clinical Collection SAM001246796
Nikkaji J409.820J
PDBe D16
PharmGKB PA131625240
PubChem 104758
PubChem: Drugs of the Future 12014189
PubChem: Thomson Pharma 16861576 14906899 16528454
Selleck Raltitrexed
SureChEMBL SCHEMBL7438
ZINC ZINC000003832372

UniChem REST Service Call:
https://www.ebi.ac.uk/unichem/rest/verbose_inchikey/IVTVGDXNLFLDRM-HNNXBMFYSA-N spacer
spacer